CTI BioPharma (CTI BioPharma) Days Sales Outstanding : 72.54 (As of Mar. 2023)

View and export this data going back to 1997. Start your Free Trial

What is CTI BioPharma Days Sales Outstanding?

CTI BioPharma's average Accounts Receivable for the three months ended in Mar. 2023 was $19.17 Mil. CTI BioPharma's Revenue for the three months ended in Mar. 2023 was $24.12 Mil. Hence, CTI BioPharma's Days Sales Outstanding for the three months ended in Mar. 2023 was 72.54.

The historical rank and industry rank for CTI BioPharma's Days Sales Outstanding or its related term are showing as below:

CTIC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.1 Med: 19 Max: 1492.63
Current: 57.35

During the past 13 years, CTI BioPharma's highest Days Sales Outstanding was 1492.63. The lowest was 2.10. And the median was 19.00.

CTIC's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 72.245 vs CTIC: 57.35

CTI BioPharma's Days Sales Outstanding declined from Mar. 2022 (96.46) to Mar. 2023 (72.54).

CTI BioPharma Days Sales Outstanding Historical Data

The historical data trend for CTI BioPharma's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma Days Sales Outstanding Chart

CTI BioPharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

Get a 7-Day Free Trial

103.83

1,492.63

104.10

CTI BioPharma Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Days Sales Outstanding	Get a 7-Day Free Trial															96.46	39.17	46.90	56.22	72.54

Competitive Comparison of CTI BioPharma's Days Sales Outstanding

For the Biotechnology subindustry, CTI BioPharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CTI BioPharma's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CTI BioPharma's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where CTI BioPharma's Days Sales Outstanding falls into.

CTI BioPharma Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

CTI BioPharma's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (0	+	15.387)	/	1 )	/	53.948	*	365
=	15.387					/	53.948	*	365
=	104.10

CTI BioPharma's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:

	Days Sales Outstanding (Q: Mar. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Mar. 2023 ))	/	count )	/	Revenue (A: Mar. 2023 )	*	Days in Period
=	( (15.387	+	22.957)	/	2 )	/	24.116	*	365 / 4
=	19.172					/	24.116	*	365 / 4
=	72.54

CTI BioPharma (NAS:CTIC) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

CTI BioPharma Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

CTI BioPharma (CTI BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (NAS:CTIC) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121

Website

https://www.ctibiopharma.com

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

Executives

James K Fong	officer: EVP & Chief Commercial Officer	C/O CTI BIOPHARMA CORP, 3101 WESTERN AVENUE, SUITE 800, SEATTLE WA 98121
Adam R Craig	director, officer: President and CEO	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
David Kirske	officer: EVP, Chief Financial Officer	C/O CTI BIOPHARMA CORP., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Michael A Metzger	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Matthew D Perry	director	ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Bvf I Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Laurent Fischer	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
David Ross Parkinson	director	C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Richard L Love	director
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104